We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Invasive Antibiotic Sensitive Infections Are Widespread In Hospitalized Infants

By LabMedica International staff writers
Posted on 03 Nov 2015
Staphylococcus aureus is a frequent cause of infection in hospitalized infants and infections due to S. More...
aureus are associated with increased mortality, morbidity, and length of hospital stay. S. aureus is the second most frequent cause of late-onset sepsis in very low-birth-weight (VLBW) infants less than 1,500 grams.

Invasive methicillin-susceptible Staphylococcus aureus infection (MSSA) caused more infections and more deaths in hospitalized infants than invasive methicillin-resistant S. aureus infection (MRSA), which suggests measures to prevent S.aureus infections should include MSSA in addition to MRSA.

Scientists at Duke University School of Medicine (Durham, NC, USA) compared demographics and mortality of infants with MRSA and MSSA at 348 neonatal intensive care units (NICUs) around the USA to determine the annual proportion of S. aureus infections that were MRSA and to contrast the risk of death after invasive MRSA and MSSA infections. Participants were infants with an invasive S. aureus infection who were discharged from calendar year 1997 through calendar year 2012.

The authors identified 3,888 of 887,910 infants (0.4%) with 3,978 invasive S. aureus infections. Infections were more commonly caused by MSSA, 2,868 of 3,978 (72.1%) than MRSA (1,110 of 3,978 (27.9%). Overall, invasive S. aureus infections had an incidence of 44.8 infections per 10,000 infants, according to the results. The annual incidence of invasive S. aureus infection increased from 1997 through 2006 and then declined modestly from 2007 through 2012. The study indicates invasive S. aureus infections were more common in infants born at less than 1,500 grams (3,061 of 136,797 or 223.8 per 10,000 infants) than in infants born at 1,500 grams or higher (915 of 748,715 or 12.2 per 10,000 infants).

There were 237 infants with invasive MSSA infections who died before hospital discharge compared to 110 infants with invasive MRSA infections. However, the proportions of infants who died after invasive MSSA and MRSA infections were similar at 237/2,474 (9.6%) and 110/926 (11.9%). The adjusted risk of death before hospital discharge and the risk of death at 7 and 30 days after invasive infection were similar between infants with invasive MSSA infection and invasive MRSA infection, the results indicate.

The authors concluded that the absolute numbers of infections and deaths due to MSSA exceed those due to MRSA. Consideration should be given to expanding hospital infection control efforts targeting MRSA to include MSSA as well. Future studies to better define the relationship between MSSA colonization and subsequent infection will help to clarify the importance of such interventions for preventing MSSA disease. The study was published on October 19, 2015, in the journal JAMA Pediatrics.

Related Links:

Duke University School of Medicine



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.